TLDR Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
This article proposes a potential link between androgenetic alopecia and COVID-19 severity. The authors suggest that studying the epidemiology of COVID-19 patients with predispositions to either lower or higher androgen receptor expression could provide insight into the role of AR in the severity of COVID-19 infection. The activation of AR can be reduced by several classes of drugs, including androgen receptor antagonists, androgen synthesis inhibitors, and antigonadotropins, which could be studied as potential therapies for COVID-19.
9 citations
,
January 2016 in “Skin Pharmacology and Physiology” The study concluded that both estrogen and androgen receptors, which decrease with age, are linked to skin aging and may be hormonally regulated.
416 citations
,
September 1997 in “Journal of Investigative Dermatology” People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
8 citations
,
February 2022 in “Journal of Clinical Medicine Research” The MATH+ protocol aims to improve COVID-19 outcomes using a combination of specific treatments.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
9 citations
,
July 2021 in “Essays in Biochemistry” Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
34 citations
,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
